Versigent (NYSE:VGNT – Get Free Report) had its price objective upped by analysts at Wells Fargo & Company from $42.00 to $48.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 11.69% from the stock’s previous close.
Other analysts also recently issued reports about the stock. Wolfe Research began coverage on shares of Versigent in a research report on Thursday, April 30th. They set an “outperform” rating and a $53.00 price target on the stock. UBS Group increased their price objective on shares of Versigent from $49.00 to $58.00 and gave the company a “buy” rating in a report on Friday, June 5th. Evercore reiterated an “outperform” rating and set a $60.00 price objective on shares of Versigent in a research note on Monday, May 18th. Zacks Research raised Versigent to a “hold” rating in a report on Thursday, April 16th. Finally, BNP Paribas Exane began coverage on Versigent in a research report on Tuesday, April 28th. They issued an “outperform” rating and a $41.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Versigent currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.33.
Check Out Our Latest Stock Analysis on VGNT
Versigent Stock Performance
Versigent (NYSE:VGNT – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $999.00 earnings per share for the quarter.
Further Reading
- Five stocks we like better than Versigent
- Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?
- Micron’s HBM Surge Could Redefine the AI Growth Story
- Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat
- European Banks Are Outperforming : Can These 3 Keep It Going?
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
